GLP-1 Medications Show Promise in Reducing Binge Eating Symptoms

A recent meta-analysis involving over 8,000 participants indicates that GLP-1 weight-loss medications might effectively alleviate binge eating symptoms in individuals with obesity. However, the authors emphasize that most of the data comes from short-term studies, necessitating further research to achieve conclusive results.

Significance of Binge Eating Disorder

Binge eating disorder (BED) affects approximately 17 million individuals globally, marked by recurrent episodes of consuming large quantities of food accompanied by a sense of loss of control. This disorder is associated with multiple physical and psychological health issues, yet treatment options remain limited. Psychological therapies can offer assistance, but their effectiveness may wane over time, and the range of available pharmacological options is narrow.

Researchers have begun to explore glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are primarily known for their roles in managing obesity and type 2 diabetes, as potential aids in reducing binge-eating episodes. These medications are believed to help regulate appetite, enhance insulin secretion, and slow gastric emptying, and may also influence brain regions linked to food rewards and cravings.

Evidence from Clinical Trials

A systematic review and meta-analysis was conducted, incorporating data from 25 randomized controlled trials (RCTs) involving 8,069 participants. The majority of participants were female (around two-thirds) and predominantly White. The trials were carried out in 12 countries across four continents, all within high- or middle-income settings, with participant age averaging 47 years and a median body mass index (BMI) of 35.8 kg/m².

The analysis revealed that participants receiving GLP-1RAs reported significant reductions in binge-eating-related symptoms compared to those on placebo or alternative treatments. This included reduced severity of binge eating, diminished disinhibition around food, and fewer episodes of feeling a loss of control during eating. Combining these measures suggested a moderate improvement in symptoms, although variability in measurement methods and participant types necessitates careful interpretation of these results.

Potential Benefits and Limitations

Those on GLP-1RAs also exhibited improvements in emotional eating and cognitive restraint, indicating a reduced tendency to eat in response to stress or negative feelings. Nevertheless, the implications of increased dietary restraint remain uncertain, as it may lead to overly rigid eating behaviors in susceptible individuals.

The most pronounced benefits were observed in a limited number of trials aimed specifically at individuals with BED. However, these studies were assessed as having a high risk of bias, meaning that definitive conclusions regarding the effectiveness of GLP-1RAs in treating BED cannot yet be drawn. Moreover, the authors noted that the research is subject to potential biases, with studies often funded by drug manufacturers, suggesting that GLP-1RAs should not be seen as a standalone solution but as a complementary therapy alongside psychological support.

THE CNP TAKEAWAY

While GLP-1 medications show promise in alleviating binge eating symptoms, their long-term effectiveness remains undetermined. Incorporating psychological support alongside these treatments is essential for holistic care.

Images courtesy of Shutterstock.

This article was prepared by CNP based on the news article entitled “The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis,” authored by Dr. Liji Thomas, MD. Read the original news article on News Medical or access the study in the NPRL GLP-1s and Mental Health research category.